Impact of two years of treatment with Elexacaftor/Tezacaftor/Ivacaftor on longitudinal changes in structural lung disease in people with Cystic Fibrosis - Results from the RECOVER trial
{{output}}
Rationale: Progressive structural lung disease (SLD) is a key hallmark of cystic fibrosis. The CFTR modulator combination Elexacaftor/Tezacaftor/Ivacaftor (ETI) is associated with short term improvements in SLD measured on chest ... ...
